| New developments in liposomal drug delivery BS Pattni, VV Chupin, VP Torchilin Chemical reviews 115 (19), 10938-10966, 2015 | 1514 | 2015 |
| Nanopreparations to overcome multidrug resistance in cancer NR Patel, BS Pattni, AH Abouzeid, VP Torchilin Advanced drug delivery reviews 65 (13-14), 1748-1762, 2013 | 356 | 2013 |
| Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma A Jhaveri, P Deshpande, B Pattni, V Torchilin Journal of controlled release 277, 89-101, 2018 | 248 | 2018 |
| Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer P Deshpande, A Jhaveri, B Pattni, S Biswas, V Torchilin Drug delivery 25 (1), 517-532, 2018 | 103 | 2018 |
| Solid lipid nanoparticles co-loaded with doxorubicin and α-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models MS Oliveira, B Aryasomayajula, B Pattni, SV Mussi, LAM Ferreira, ... International journal of pharmaceutics 512 (1), 292-300, 2016 | 72 | 2016 |
| Targeted Drug Delivery Systems: Strategies and Challenges B Pattni, V Torchilin Targeted Drug Delivery : Concepts and Design, 3 - 38, 2015 | 44 | 2015 |
| Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG BS Pattni, A Jhaveri, I Dutta, JD Baleja, A Degterev, V Torchilin International journal of pharmaceutics 532 (1), 149-156, 2017 | 23 | 2017 |
| Targeting of micelles and liposomes loaded with the pro-apoptotic drug, NCL-240, into NCI/ADR-RES cells in a 3D spheroid model BS Pattni, SG Nagelli, B Aryasomayajula, PP Deshpande, A Kulkarni, ... Pharmaceutical research 33, 2540-2551, 2016 | 19 | 2016 |
| Combination Nanopreparations of a Novel Proapoptotic Drug–NCL-240, TRAIL and siRNA R Riehle, B Pattni, A Jhaveri, A Kulkarni, G Thakur, A Degterev, ... Pharmaceutical research 33, 1587-1601, 2016 | 17 | 2016 |
| Silk-based products and methods of use M Santos, S Delisle, A Tweed-Kent, L Easthon, BS Pattni US Patent App. 16/762,547, 2021 | 1 | 2021 |
| Vesicle compositions for oral delivery J Bolen, R Shyam, R Bogorad, K Krumova, B Pattni, N Pilla, A Singh US Patent App. 17/791,411, 2023 | | 2023 |
| Ocular applications of silk-based products M Santos, S Delisle, A Tweed-Kent, L Easthon, BS Pattni US Patent App. 16/762,544, 2021 | | 2021 |
| Oral dosage form with surface delivery of active agent D Bonner, J Jantz, TH Jozefiak, B Pattni WO Patent WO2020072729A1, 2020 | | 2020 |
| Milk vesicles for use in delivering biological agents J Bolen, R Shyam, N Pilla, K Krumova, B Pattni, D Bonner WO Patent WO2020010161A1, 2020 | | 2020 |
| Ocular applications of silk-based products M Santos, S Delisle, A Tweed-Kent, L Easthon, B Pattni WO Patent WO2,019,094,702, 2019 | | 2019 |
| SILK-BASED PRODUCTS AND METHODS OF USE M Santos, S Delisle, A Tweed-Kent, L Easthon, B Pattni WO Patent WO 2019/094700 A l, 2019 | | 2019 |
| Lipid-based delivery systems for combinations of novel anti-cancer drug candidate, NCL-240, and other anti-cancer agents BS Pattni NORTHEASTERN UNIVERSITY BOSTON, 2017 | | 2017 |
| Cell toxicity evaluation of lipid-based nanoparticles delivering survivin-siRNA and Doxil in sensitive and resistant human carcinoma BS Pattni | | 2011 |
| Cytotoxic activity of solid lipid nanoparticles loaded with Doxorrubicin and α-Tocopheryl Succinate against resistant cell line MS Oliveira, RS Fernandes, ALB Barros, LAM Ferreira, B Aryasomayajula, ... | | |
| Combined administration of novel drug, NCL-240, and 2-DG in cancer cells B Pattni, A Jhaveri, I Dutta, A Degterev, V Torchilin | | |
Vladimir TorchilinUniversity Professor, Northeastern UniversityVerified email at neu.edu
